Modification of Common Diabetes Drug Improved Blood Sugar Control in Mouse Model

Article title: Reduced incretin receptor trafficking upon activation enhances glycemic control and reverses obesity in diet-induced obese mice Authors: Rathin Bauri, Shilpak Bele, Jhansi Edelli, Neelesh C. Reddy, Sreenivasulu Kurukuti, Tom Devasia, Ahamed Ibrahim, Vishal Rai, Prasenjit Mitra From the authors: “Chronic…

Should heart patients consider taking weight loss medications?

Over the last year, prescriptions for medications that can accelerate weight loss in people with diabetes, or without it, have skyrocketed. But how can these weight loss medications affect the heart? A preventive cardiologist shares how this shifting landscape might affect cardiovascular care and how he advises his patients.

SGLT2 inhibitors and GLP1 receptor antagonists improve type-2 diabetes outcomes, but are not cost effective

A cost-effectiveness study of sodium–glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP1) receptor agonists has found that the use of these medications as first-line treatment for type-2 diabetes would improve outcomes, but their costs would need to decrease by at least 70 percent to be cost-effective. The study is published in Annals of Internal Medicine.